Close Menu

NEW YORK (GenomeWeb) – Cepheid said today that it is broadening its collaboration with the Foundation for Innovative New Diagnostics to bring point-of-care tuberculosis diagnostics to all levels of the health system in low- and middle-income countries.

Specifically, the partners will evaluate the performance of Cepheid's new GeneXpert Omni system and Xpert MTB/RIF Ultra test, and assess the Omni's cloud-based connectivity. All resulting data from the evaluation will be made publicly available, Cepheid said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.